Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30627643 | 0.83 | NQO2 (0.63) | NQO2MTNR1AIDO1CTSSCTSK | |
| SCHEMBL30627602 | 0.82 | NQO2 (0.62) | NQO2MTNR1AIDO1CTSSCTSK | |
| SCHEMBL30627583 | 0.82 | NQO2 (0.62) | NQO2MTNR1AIDO1CTSSCTSK | |
| SCHEMBL30627627 | 0.82 | NQO2 (0.62) | NQO2MTNR1AIDO1CTSSCTSK | |
| SCHEMBL30627624 | 0.82 | NQO2 (0.62) | NQO2MTNR1AIDO1CTSSCTSK | |
| SCHEMBL30627657 | 0.82 | NQO2 (0.62) | NQO2MTNR1AIDO1CTSSCTSK | |
| SCHEMBL30627584 | 0.82 | NQO2 (0.62) | NQO2MTNR1AIDO1CTSSCTSK | |
| SCHEMBL1579453 | 0.81 | NQO2 (0.75) | NQO2MTNR1ACTSSCTSKKDM4A | |
| SCHEMBL20564104 | 0.81 | NQO2 (0.47) | NQO2MTNR1ASLC2A1MTNR1B | |
| SCHEMBL30627590 | 0.79 | NQO2 (0.58) | NQO2MTNR1AIDO1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | NQO2 1057/4885MTNR1A 222/4885IDO1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.